IVA
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Traditional value metrics are non-existent or alarming; stock trades at a massive premium to current revenue.
- P/S ratio of 137.80 is unsustainable
- Negative Price/Book ratio
- No Graham Number available
Future value is entirely dependent on clinical catalysts, not current growth rates.
- High analyst target price ($15.13)
- Strong Buy recommendation
- Revenue growth is crashing (-79.6%)
Long-term performance is poor, though short-term momentum has been volatile.
- Recent 1Y recovery (+70.8%)
- 5Y change is -63.3%
- Consistent negative earnings
Health is precarious; the Piotroski score prevents a total failure rating, but the balance sheet is weak.
- Piotroski F-Score of 4/9 (Stable)
- Negative equity
- Massive operating losses
Typical for biotech; all capital is reinvested or consumed by R&D.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IVA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IVA
Inventiva S.A.
Primary
|
-63.3% | +67.0% | +70.8% | +15.6% | -20.7% | -3.8% |
|
INNV
InnovAge Holding Corp.
Peer
|
-65.5% | +9.5% | +197.1% | +60.5% | -4.5% | +7.8% |
|
ABCL
AbCellera Biologics Inc.
Peer
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
|
GERN
Geron Corporation
Peer
|
+23.9% | -12.9% | +26.6% | +26.6% | +8.0% | +6.0% |
|
AKTS
Aktis Oncology, Inc.
Peer
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IVA
Inventiva S.A.
|
NEUTRAL | $1.09B | - | -% | -% | $5.26 | |
|
INNV
InnovAge Holding Corp.
|
BEARISH | $1.11B | 164.0 | 1.2% | 0.7% | $8.2 | Compare |
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | Compare |
|
GERN
Geron Corporation
|
NEUTRAL | $1.13B | - | -33.0% | -45.4% | $1.76 | Compare |
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning IVA from our newsroom.